Relmada Therapeutics Strengthens Board of Directors with Appointments of Life Sciences Industry Veterans, Eric Schmidt, Ph.D., and John Glasspool
NEW YORK, Dec. 20, 2019 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced the appointments of life sciences industry veterans, Eric Schmidt, Ph.D., and John Glasspool, to the Company's Board of Directors...
Login to comment.